1.
Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al.: Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012;380:1840-1850.
[PubMed]
2.
Hildesheim A, Hadjmichael O, Schwartz P, et al.: Risk factors for rapid onset cervical cancer. Am J Obstet Gynecol 1999;180:571-577.
[PubMed]
3.
Liebrich C, Brummer O, Von WR, et al.: Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. Eur J Gynaecol Oncol 2009;30:45-48.
[PubMed]
4.
Herfs M, Yamamoto Y, Laury A, et al.: A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012;109:10516-10521.
[PubMed]
5.
Arbyn M, Castellsagué X, de Sanjosé S, et al.: Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-2686.
[PubMed]
6.
Kocken M, Helmerhorst TJ, Berkhof J, et al.: Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011;12:441-450.
[PubMed]
7.
Siebert U, Sroczynski G, Hillemanns P, et al.: The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health 2006;16:185-192.
[PubMed]
8.
Chao A, Becker TM, Jordan SW, Darling R, Gilli-land FD, Key CR: Decreasing rates of cervical cancer among American Indians and Hispanics in New Mexico (United States). Cancer Causes Control 1996;7:205-213.
[PubMed]
9.
Arbyn M, Ronco G, Anttila A, et al.: Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30 (suppl 5):F88-F99.
[PubMed]
10.
Ronco G, Dillner J, Elfstrom KM, et al.: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-532.
[PubMed]
11.
Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ: Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009;46 (suppl 3):S1-S4.
[PubMed]
12.
Petry KU, Böhmer G, Iftner T, Davies P, Brummer O, Kühnle H: Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia. Am J Obstet Gynecol 2002;186:28-34.
[PubMed]
13.
Petry KU, Breugelmans JG, Benard S, Lamure E, Littlewood KJ, Hillemanns P: Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol 2008;29:345-349.
[PubMed]
14.
TOMBOLA Group: Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study. BMJ 2009;339:b2549.
[PubMed]
15.
Moss EL, Arbyn M, Dollery E, et al.: European Federation of Colposcopy quality standards Delphi consultation. Eur J Obstet Gynecol Reprod Biol 2013;170:255-258.
[PubMed]
16.
Cuzick J, Clavel C, Petry KU, et al.: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101.
[PubMed]
17.
Petry KU, Menton S, Menton M, et al.: Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-1577.
[PubMed]
18.
Sawaya GF, McConnell KJ, Kulasingam SL, et al.: Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003;349:1501-1509.
[PubMed]
19.
Arbyn M, Kyrgiou M, Simoens C, et al.: Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.
[PubMed]
20.
Petry KU, Rinnau F, Bohmer G, et al.: Annual Papanicolaou screening for 5 years among human papillomavirus-negative women. BMC Cancer 2013;13:379.
[PubMed]
21.
McCredie MR, Sharples KJ, Paul C, et al.: Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-434.
[PubMed]
22.
Petry KU: Management options for cervical intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol 2011;25:641-651.
[PubMed]
23.
Luyten A, Scherbring S, Reinecke-Luthge A, et al.: Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany - experience over 3 years. J Clin Virol 2009;46(suppl 3):S5-10.
[PubMed]
24.
Gesellschaft der epidemiologischen Krebsregister in Deutschland/Robert Koch-Institut: Krebs in Deutschland 2009-2010, Häufigkeiten und Trends, ed 9. Berlin, 2013. www.ekr.med.uni-erlangen.de/GEKID/Doc/krebs_in_deutschland_2009_2010.pdf.
[PubMed]
25.
Gesellschaft der epidemiologischen Krebsregister in Deutschland/Robert Koch-Institut: Krebs in Deutschland 2005-2006, Häufigkeiten und Trends, ed 7. Berlin, 2010.
26.
Chen T, Jansen L, Gondos A, et al.: Survival of cervical cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. Acta Oncol 2012;51:915-921.
27.
Traut HF, Papanicolaou GN: Cancer of the uterus: the vaginal smear in its diagnosis. Cal West Med 1943;59:121-122.
[PubMed]
28.
Moyer VA: Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156:880-891.
[PubMed]
29.
Whitlock E P, Vesco KK, Eder M, et al.: Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:687-697.
[PubMed]
30.
Sankaranarayanan R, Nene MB, Shastri SS, et al.: HPV Screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-1394.
[PubMed]
31.
Arbyn M, Raifu AO, Weiderpass E, et al.: Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009;45:2640-2648.
[PubMed]
32.
Wörmann B: Zervixkarzinom: Systemische Therapie in einem kurativen multimodalen Konzept. Onkologe 2012;18:56-60.
33.
Anttila A, Pokhrel A, Kotaniemi-Talonen L, et al.: Cervical cancer patterns with automation-assisted and conventional cytological screening: a randomized study. Int J Cancer 2011;128:1204-1212.
[PubMed]
34.
Petry KU: Sekundärprävention des Zervixkarzinoms. Onkologe 2012;18:27-34.
35.
Hellsten C, Sjöström K, Lindqvist PG: A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. BJOG 2008;115:212-218.
[PubMed]
36.
Müller H: Modernes Gesundheitsmanagement und physische Anthropologie. Bulletin der Schweizerischen Gesellschaft für Anthropologie 2010;16:35-46.
37.
Kyrgiou M, Arbyn N, Martin-Hirsch P, et al.: Increased risk of preterm birth after treatment for CIN. BMJ 2012;345:e5847.
[PubMed]
38.
AWMF S2 Leitlinie: Zervixkarzinom. Interdisziplinäre Leitlinie zur Diagnostik und Therapie des Zervixkarzinoms, 2008. www.awmf.org/uploads/tx_szleitlinien/032-033l_S2k_Zervixkarzinom-ung.pdf.
39.
Schiffman M, Castle PE, Jeronimo J, et al.: Human papillomavirus and cervical cancer. Lancet 2007; 370:890-907.
[PubMed]
40.
Bosch FX, Broker TR, Forman D, et al.: Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013;315:H1-H31.
[PubMed]
41.
Crosbie EJ, Einstein MH, Franceschi S, et al.: Human papillomavirus and cervical cancer. Lancet 2013;382:889-899.
[PubMed]
42.
Walboomers JM, Jacobs MV, Manos MM: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
[PubMed]
43.
Guan P, Howell-Jones R, Li N, et al.: Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131:2349-2359.
[PubMed]
44.
Brotherton JM, Fridman M, May CL, et al.: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an eco-logic study. Lancet 2011;377:2085-2092.
[PubMed]
45.
Schiffman M, Solomon D: Cervical-cancer screening with human papillomavirus and cytologic contesting. N Engl J Med 2013;369:2324-2331.
[PubMed]
46.
Dillner J, Rebolj M, Birembaut P, et al.: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
[PubMed]
47.
Sroczynski G, Schnell-Inderst P, Mühlberger N, et al.: Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis. Eur J Cancer 2011;47:1633-1646.
[PubMed]
48.
Schenck U, von Karsa L: Cervical cancer screening in Germany. Eur J Cancer 2000;36:2221-2226.
[PubMed]
49.
Arbyn M, Anttila A, Jordan J, et al.: European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition - summary document. Ann Oncol 2010;21:448-458.
[PubMed]
50.
Schneider A, Kraus H, Schuhmann R, Gissmann L: Papillomavirus infection of the lower genital tract: detection of viral DNA in gynecological swabs. Int J Cancer 1985;35:443-448.
[PubMed]
51.
De Villiers EM, Wagner D, Schneider A, Wesch H, Miklaw H, Wahrendorf J, Papendick U, zur Hausen H: Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Lancet 1987;2:703-706.
52.
Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez R, Denton K, Hariri J, Keller T, von Knebel Doeberitz M, Neumann HH, Puig-Tintore LM, Sideri M, Rehm S, Ridder R; PALMS Study Group: Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013;105:1550-1557.
[PubMed]
53.
Uijterwaal MH, Witte BI, van Kemenade FJ, Rijkaart D, Ridder R, Berkhof J, Balfoort-van der Meij GA, Bleeker MC, Snijders PJ, Meijer CJ: Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study. Br J Cancer 2014;110:1579-1586.
[PubMed]
54.
Petry KU, Luyten, Scherbring S: Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany. Gynecol Oncol 2013;128:282-287.
[PubMed]
55.
No authors listed: Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programs. Br Med J 1986;293:659-664.
[PubMed]
56.
Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J: Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011;22:505-515.
[PubMed]
57.
Bettigole C: The thousand-dollar Pap smear. N Engl J Med 2013;369:1486-1487.
[PubMed]
You do not currently have access to this content.